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Abstract
 
To elucidate the role of class switch recombination (CSR) and somatic hypermutation (SHM)
in virus infection, we have investigated the influence of the primary and secondary infections of
influenza virus on mice deficient of activation-induced cytidine deaminase (AID), which is
absolutely required for CSR and SHM. In the primary infection, AID deficiency caused no
significant difference in mortality but did cause difference in morbidity. In the secondary infec-
 
tion with a lethal dose of influenza virus, both AID
 
 
 
/
 
  
 
and AID
 
 
 
/
 
  
 
mice survived completely.
However, AID
 
 
 
/
 
  
 
mice could not completely block replication of the virus and their body
weights decreased severely whereas AID
 
 
 
/
 
  
 
mice showed almost complete prevention from the
reinfection. Depletion of CD8
 
  
 
T cells by administration of an anti-CD8 monoclonal antibody
caused slightly severer body weight loss but did not alter the survival rate of AID
 
 
 
/
 
  
 
mice in sec-
ondary infection. These results indicate that unmutated immunoglobulin (Ig)M alone is capable
of protecting mice from death upon primary and secondary infections. Because the titers of vi-
rus-neutralizing antibodies were comparable between AID
 
 
 
/
 
  
 
and AID
 
 
 
/
 
  
 
mice at the time of
the secondary infection, a defect of AID
 
 
 
/
 
  
 
mice in protection of morbidity might be due to the
absence of either other Ig classes such as IgG, high affinity antibodies with SHM, or both.
Key words: AID • class-switch recombination • somatic hypermutation • antiviral immunity • 
antibody
 
Introduction
 
Prevention of viral infection by antibodies depends on di-
verse mechanisms such as prevention of viral attachment to
the host cell (1, 2), activation of the complement system (3,
4), opsonization (5), antibody-dependent cell-mediated cy-
totoxicity (6, 7), and inhibition of the release of daughter
viruses from infected cells (8–10). Such a wide variety of
antibody activities are mediated by a generation of various
classes of antibody (IgG, IgA, and IgE) besides IgM and
IgD through class switch recombination (CSR; 11). Each
class of antibody differs in size, in vivo half-life, ability to
bind to Fc receptors, ability to activate complement, sensi-
tivity to digestion by proteolytic enzymes, and the ten-
dency to aggregate (12), and thus CSR determines how
captured antigens are eliminated or the locations to which
the antibody is delivered.
Several investigations suggest that CSR may have a vital
contribution to the protection against influenza virus infec-
tion and/or recovery from the infection (13, 14). For ex-
ample, different antiviral activities among Ig classes have
been reported (13). The passive transfer of virus-specific
mAb of IgG class exerted prophylactic and therapeutic effect
against influenza virus infection in the SCID mouse model,
whereas the transfer of IgM or IgA exerted only prophy-
lactic effect. The protective role of Fc receptor–mediated
phagocytosis in influenza virus infection also suggests the
importance of CSR (14) because the affinity to the Fc re-
ceptor is different among antibody classes, particularly mice
IgG subclasses IgG1, IgG2a, and IgG2b, which are able to
bind to Fc
 
  
 
receptors with higher affinity than IgG3 (7).
Although these data support the assumption that CSR plays
a role in pathology of influenza virus infection, the direct
evidence for the involvement of CSR in protection or re-
covery from viral infection is still missing.
In addition to CSR, another prominent alteration of the
Ig gene sequence, somatic hypermutation (SHM), plays a
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critical role in antibody maturation (15). SHM accumu-
lates massive point mutations in the V exon and gives rise
to affinity maturation of antibodies in association with se-
lection of B cells expressing high affinity Igs on their sur-
face. The importance of SHM in secondary influenza virus
infection is suggested indirectly. Sequence analysis of sev-
eral antibodies against influenza virus has revealed the ac-
cumulation of mutations in secondary, but rarely in pri-
mary, antibodies (16).
Recently, activation-induced cytidine deaminase (AID)
has been shown to be essential for CSR and SHM (17).
The AID gene encodes a protein that has low homology
(31%) with apolipoprotein B mRNA-editing enzyme cata-
lytic polypeptide 1, a type of cytidine deaminase (18). AID
mRNA was selectively expressed in activated splenic B
cells and particularly germinal center B cells (17, 19). AID-
deficient (AID
 
 
 
/
 
 
 
) mice, generated by gene-targeted mu-
tation, showed complete abrogation of CSR and SHM and
also elevated IgM levels in sera as compared with heterozy-
gous mice (AID
 
 
 
/
 
 
 
; 17). In human, mutations in the AID
gene cause the autosomal recessive hyper IgM syndrome
type II that is characterized by higher levels of IgM and the
absence of all other Ig classes and SHM (19). Furthermore,
ectopic expression of AID alone can induce CSR and
SHM in fibroblasts (20, 21).
Availability of AID
 
 
 
/
 
  
 
mice that develop normal he-
matopoietic cells except for B cells that are deficient in
CSR and SHM (17), enables us to investigate the roles of
CSR and SHM in viral infections. Here we report that
IgM without SHM is capable of supporting complete sur-
vival of mice at primary and secondary influenza virus in-
fections with 1 PFU (sublethal dose) and 1,000 PFU (lethal
dose), respectively. However, at primary infection AID
 
 
 
/
 
 
 
mice showed delay in elimination of virus and in recovery
of body weights and at secondary infection AID
 
 
 
/
 
 
 
, but
not AID
 
 
 
/
 
 
 
, mice showed virus replication and weight
loss, indicating that either CSR, SHM, or both play critical
roles in the virus infection.
 
Materials and Methods
 
Animals and Viruses.
 
AID
 
 
 
/
 
  
 
and AID
 
 
 
/
 
  
 
mice were bred
and maintained in the Animal Center of Kyoto University. These
mice have (CBA 
 
  
 
C57BL/6) 
 
  
 
C57BL/6 background and their
characters were previously reported (17). All mice used were be-
tween 4–6 wk of age. Procedures that involved mice were ap-
proved by institutional guidelines for animal care.
Influenza virus, mouse-adapted A/PR/8/34 (mPR8), was
grown in the allantoic cavity of 10-d-old embryonated chicken
eggs. Virus titers were determined by plaque or 50% tissue culture
infectious dose (TCID
 
50
 
) assay on MDCK cells. Purified mPR8
used for ELISA was obtained by velocity density gradient centrif-
ugation through a 20–50% linear sucrose gradient. The virion-
containing fractions were stored at 
 
 
 
80
 
 
 
C until use.
 
Virus Inoculation.
 
For the primary influenza virus infection,
mPR8 was appropriately diluted with PBS containing 0.2% bo-
vine serum albumin (BSA-PBS). Mice were anesthetized with
ether and then inoculated intranasally with 50 
 
 
 
l mPR8. For the
secondary influenza virus infection, mice were inoculated with 1
 
PFU of mPR8 as described above and 6 wk later they were chal-
lenged intranasally with a lethal dose (100 LD
 
50 
 
or 1,000 PFU) of
mPR8 in 50 
 
 
 
l BSA-PBS. These mice were monitored daily for
their survival and weight for 4 wk.
 
Titration of Virus in the Lungs.
 
Lungs were homogenized in
2.5 ml ice cold RPMI 1640. The homogenates were centrifuged
at 500 
 
g
 
 for 5 min to remove cell debris and the supernatants
were stored at 
 
 
 
80
 
 
 
C until assay. To determine TCID
 
50 
 
of virus
in the lungs, confluent monolayers of MDCK cells on 96-well
microtiter plates were infected with 10-fold serial dilutions of
lung homogenates. After 6–7 d of incubation at 34
 
 
 
C, MDCK
cells were fixed and stained with crystal violet to detect the cyto-
pathic effect (CPE) caused by influenza virus infection. The wells
with CPE were counted and TCID
 
50 
 
was calculated according to
the Reed and Muench method.
 
Detection of Influenza Virus–specific Antibodies in Sera.
 
Influ-
enza virus–specific antibodies in sera were detected by ELISA as
previously described (22). In brief, the wells of 96-well microtiter
plates were coated with purified PR8 virus that had been solubi-
lized with disruption buffer (0.05 M Tris-HCl, pH 7.8, contain-
ing 0.5% Triton X-100, and 0.6 M KCl) at room temperature.
Diluted sera were transferred onto the viral protein–coated plates.
After incubation for 60 min at room temperature, the plates were
washed and horseradish peroxidase–conjugated secondary anti-
body was added to the wells. The secondary antibodies used in
this study were sheep anti–mouse Igs (Amersham Biosciences) for
total antibody detection, goat anti–mouse IgM specific for 
 
 
 
heavy chain (Zymed Laboratories), and rat anti–mouse IgG spe-
cific for 
 
  
 
heavy chains (Zymed Laboratories). Endpoint antibody
titers were expressed as the reciprocal dilution of the last dilution
that gave optical densities at 405 nm of 
 
 
 
0.1 U above the optical
density of negative controls.
Virus-neutralizing titers of sera were determined according to
Benton et al. (23), and the reciprocal dilution of the last dilution
that reduced the CPE by 50% was taken as the neutralizing titer.
 
In Vivo Depletion of CD8
 
  
 
T Cells.
 
AID
 
 
 
/
 
  
 
mice were de-
pleted of CD8
 
  
 
T cells by intraperitoneal administration of di-
luted mouse ascites fluid containing the rat anti–mouse CD8
mAb 53-6.7. Each mouse received 0.5 ml ascites fluid 3 d before
influenza virus challenge, on the day of the challenge, on day 3
after the challenge, and then at 2-d intervals until the completion
of the experiment. To verify depletion of CD8
 
  
 
T cells, flow cy-
tometric analysis was performed using a FACScan™ (Becton
Dickinson). Splenocytes (5 
 
  
 
10
 
5 
 
cells) were prepared from mice
and stained with FITC-conjugated anti-CD8 mAb (YTS169.4;
Cedarlane) and PE-conjugated anti-CD4 mAb (GK1.5; Leinco
Technologies, Inc.). By the analysis, it was confirmed that 93–
99% of CD8
 
  
 
T cells were depleted by this procedure.
 
Results and Discussion
 
AID Is Not Essential to Survival of Mice from Primary Influ-
enza Infection.
 
To examine whether CSR and SHM are
required to protect from primary influenza virus infection,
AID
 
 
 
/
 
  
 
and AID
 
 
 
/
 
  
 
mice were inoculated intranasally with
various doses of mPR8 and their survival and morbidity,
which was monitored by weight loss, was measured (Fig. 1).
The mice of both genotypes showed no significant differ-
ence in the survival curve with the identical LD
 
50 
 
value
(4.68 PFU) of mPR8. Regardless of genotypes, the mice
inoculated with 100 PFU mPR8 were completely killed by
day 10 and the inoculation of 10 PFU mPR8 caused 80%T
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death by day 21 (Fig. 1 A). All of the mice of both geno-
types survived when inoculated with 1 PFU mPR8.
The rate of weight loss by virus infection was dependent
on inoculated doses of the virus in both genotypes and the
mice inoculated with 
 
 
 
10 PFU reduced their body
weights much more rapidly until death than 1 PFU–
infected mice (Fig. 1 B). The average weight loss by 1 PFU
mPR8 infection was slightly greater in AID
 
 
 
/
 
  
 
mice than
that in AID
 
 
 
/
 
  
 
mice. The lowest weight of mice and the
day when mice showed the lowest weight were statistically
different between AID
 
 
 
/
 
  
 
mice (
 
n 
 
  
 
20) and AID
 
 
 
/
 
  
 
mice
(
 
n 
 
  
 
27). Student’s 
 
t
 
 test for the lowest weight and Mann-
Whitney’s U-test for the lowest day revealed P 
 
  
 
0.005
and P 
 
  
 
0.01, respectively. In AID
 
 
 
/
 
 
 
 mice the recovery
from the weight loss was also delayed. When the day on
which mice regained to the initial body weight was com-
pared, the difference between 2 genotypes was statistically
significant (Mann-Whitney’s U test, P 
 
  
 
0.05).
In spite of similar survival rate of AID
 
 
 
/
 
  
 
and AID
 
 
 
/
 
 
 
mice at primary influenza virus infection, there was differ-
ence in the replication of mPR8 in the lungs between
AID
 
 
 
/
 
  
 
and AID
 
 
 
/
 
  
 
mice (Fig. 2). The virus titers in the
lungs of mice infected with 1 PFU mPR8 increased simi-
larly in both genotypes until day 6. However, considerable
titers of virus were detected on day 8 in AID
 
 
 
/
 
  
 
mice, but
not in AID
 
 
 
/
 
  
 
mice, indicating a defect in virus elimination
in AID
 
 
 
/
 
  
 
mice. By day 10, virus was eliminated in both
AID
 
 
 
/
 
  
 
and AID
 
 
 
/
 
  
 
mice. The slightly slower elimination
of virus in AID
 
 
 
/
 
  
 
mice is consistent with their delayed re-
covery of the body weight.
 
Induction of Similar Levels of Virus Neutralizing Antibodies in
AID-proficient and -deficient Mice.
 
Antibody response spe-
cific to mPR8 was clearly altered by AID deficiency (Fig.
3). The amounts of total antibodies specific to mPR8 in
sera began to increase on day 8 in AID
 
 
 
/
 
  
 
mice inoculated
with 1 PFU mPR8, reaching a plateau around day 28. The
plateau level was maintained until secondary virus infection
(day 42). In AID
 
 
 
/
 
  
 
mice, the response of virus-specific to-
tal antibodies was basically similar to that in AID
 
 
 
/
 
  
 
mice.
An abrupt increment of antibodies was detected on day 8
and then their amounts gradually increased to a plateau
level in AID
 
 
 
/
 
  
 
mice, which was maintained until second-
ary virus infection like in AID
 
 
 
/
 
  mice. Although the aver-
age plateau level in AID /  mice was lower than that in
AID /  mice, the time period to reach the plateau level
was shorter in AID /  mice; around day 10 as compared
with around day 28 in AID /  mice.
When IgM and IgG classes in virus-specific antibodies
were quantified separately, the differences between AID / 
and AID /  mice were much more obvious. The time
course of IgM levels in sera of AID /  mice was essentially
similar to that of total antibodies as expected, whereas the
Figure 1. Susceptibility of AID /  mice to influenza
virus infection. Five mice of each genotype, AID / 
and AID / , were inoculated intranasally with various
doses of mPR8 ( , 100 PFU;  , 101 PFU;  , 102
PFU) and monitored for 4 wk for their survival (A) and
body weight (B) daily. The weight is expressed by per-
cent of the weight on day 0 and datum points represent
the mean of survived mice. Dashed line shows basal
level of body weight and error bars represent standard
deviations.
Figure 2. Virus replication in the lungs of AID /  mice. Three to five
mice of each genotype, AID /  or AID / , were inoculated intranasally
with 1 PFU mPR8. At indicated days after inoculation, lungs were col-
lected and homogenized. Virus titers in the homogenates were deter-
mined on MDCK cells as described in Materials and Methods. Results are
expressed as the mean titer   standard deviation. N.D., not detectable.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
1782 Unmutated IgM Can Protect Mice
level of IgM in AID /  mice decreased after the peak on
day 8 and in most mice (three of the five mice in Fig. 3 and
in other experiments 16 of 22 mice), virus-specific IgM
was below the detectable level on day 41. The long-main-
tained high level of IgM in AID /  mice is probably due to
the absence of CSR and suggests that the CSR may con-
tribute to the reduction of antigen-specific IgM response in
wild-type mice.
As expected, the IgG response in AID /  mice was to-
tally different from that in AID /  mice. In the sera of
mPR8-infected AID /  mice, virus-specific IgG was de-
tectable on day 8, only 2 d later than the detection of IgM,
and then gradually increased until day 28 and thereafter
maintained a plateau level like the time course of total anti-
bodies. In AID /  mice, virus-specific IgG was not de-
tected at all.
The time course of neutralizing antibody response was
similar between the two genotypes in spite of the differ-
ence in the total antibody titers. Less amounts of virus-spe-
cific total antibodies might be compensated by higher levels
of IgM in sera of AID /  mice.
AID Is Required for Inhibition of Viral Replication but Not for
Host Survival at the Secondary Lethal Challenge. Next, we
examined the role of CSR and SHM in the secondary in-
fluenza virus infection. AID-deficient and -proficient mice
were inoculated with 1 PFU mPR8 and 6 wk later the
mice were challenged intranasally with a lethal dose (1,000
PFU or 100 LD50) of mPR8. Regardless of the genotypes,
all of the challenged mice survived completely (unpub-
lished data).
The morbidity assessed by the body weight change,
however, was distinct between AID /  and AID /  mice.
Whereas AID /  mice showed no sign of the decrease in
the body weight, AID /  mice lost their weight severely
for the first 6 d after the challenge (Fig. 4 A). Weight loss
was recovered to their initial body weights by 17 d after
the challenge in all of AID /  mice. The replication of
secondarily challenged virus was completely prevented in
AID /  mice with no detection of virus during a 5-d pe-
riod after infection. In contrast, vigorous viral replication
was observed in preimmunized AID /  mice challenged
with the lethal dose of mPR8 (Table I). The titers of virus
recovered in preimmunized AID /  mice were almost
equivalent to those in mock-immunized AID /  mice
(unpublished data). These data indicate that the primary
virus immunization of AID /  mice was incompetent for
prevention of viral replication as well as of morbidity upon
secondary virus infection.
Virus-specific IgM titers in sera were not significantly
increased by the secondary influenza virus infection in
AID /  mice (Fig. 3). On the other hand, in AID / 
mice, virus-specific IgM as well as total antibodies began
to increase on day 5 after challenge (47 d after primary in-
fection) and kept increasing until day 10. The total virus-
specific antibodies on day 10 were comparable between
AID /  and AID /  mice.
Although AID /  mice survived from secondary influ-
enza virus infection, severe weight loss and vigorous viral
replication were observed. By contrast, immunocompetent
AID /  mice completely protected themselves from the le-
thal virus challenge in the secondary infection. It is remark-
able that virus was not detected even on day 1 after chal-
lenge without significant increase in the antibody titer in
AID /  mice (Figs. 3 and 4 A, and Table I). We assume
that inoculated virus was completely neutralized with the
antibody induced by primary infection in AID /  mice but
not in AID /  mice.
Because the memory CTL response against influenza vi-
rus in AID /  mice was comparable to that in AID / 
mice (unpublished data) and virus-specific memory CTL
response was first observed in the lymph nodes attached to
lungs on day 2 after secondary influenza virus infection
(24), it is unlikely that the CD8  CTL response played a
major role in the protection against secondary virus infec-
tion observed in AID /  mice. Given the fact that the pro-
tection against secondary virus infection of the lethal dose
is not complete in AID /  mice, it is likely that virus-spe-
cific IgG or IgM antibodies with SHM play critical roles in
protecting mice from the secondary influenza virus chal-
lenge. In fact, Palladino et al. (13) have demonstrated that
adoptive transfer of monoclonal IgM provides mice with
complete protection and blockade of viral replication, al-
though therapeutically ineffective, upon lethal influenza
virus infection. The low avidity of IgM to virus antigen
because of the lack of SHM could be the cause of less effi-
Figure 3. Influenza virus–specific antibody response in AID /  mice.
Mice of each genotype, AID /  or AID / , were intranasally inoculated
with 1 PFU mPR8 and 42 d later they were challenged intranasally with
a lethal dose (1,000 PFU) of mPR8 virus (arrows). Blood was taken at the
indicated time points and virus-specific titers of total antibodies, IgM and
IgG, and virus-neutralizing antibody titers in the sera were determined as
described in Materials and Methods. Symbols and error bars represent
means and standard deviations for three to five mice per group. The limit
of detection in this assay was 42.6. Titers  42.6 were set to 42 for calcula-
tion of means and standard deviations.T
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cient protection against the secondary virus challenge in
AID /  mice.
CD8  CTL Is Not Required for Survival of AID /  Mice at
the Secondary Lethal Challenge. Although the critical role
of CTL in secondary virus infection of AID /  mice is un-
likely, contribution of CD8  CTL to the protection of
AID /  mice is not excluded. To clarify this point, preim-
munized AID /  mice were depleted of CD8  T cells by
the administration of an anti-CD8 mAb and challenged
with a lethal dose of influenza virus. CD8  CTL-depleted
AID /  mice showed slightly severer body weight loss than
challenged control AID /   mice that had been mock
treated and maintained intact CD8  CTL (Fig. 4 B). The
depletion of CD8  CTL, however, did not alter the sur-
vival rate of AID /  mice and all of the immunized AID / 
mice survived regardless of depletion of CD8  CTL. These
data indicate that the survival of AID /  mice at secondary
lethal virus challenge should be mediated mainly by virus-
specific antibody and not by CTL.
Unmutated IgM Is Sufficient for Survival of Mice from Influ-
enza Virus Infection. Survival rate in AID /  mice was simi-
lar to those in AID /  mice, whereas the clearance of virus
and recovery of body weight in AID /  mice was delayed.
These data indicate that in the early phase of influenza virus
infection AID does not play a critical role in the survival
battle against the virus. It is noteworthy that low levels of
virus-specific IgM were already reproducibly detected 1 d
after infection in AID /  mice, which is in general agree-
ment with increased levels of IgM in these animals (17).
IgM in AID /  mice should not have SHM and are un-
likely to be induced by virus infection because the same
level of virus-specific IgM was detected in the PBS-inocu-
lated AID /  mice (unpublished data). Because the sharp
increase of virus-specific antibodies roughly coincided with
the decrease of virus titers in the lungs of AID /  and
AID /  mice (Figs. 2 and 3), we assume that virus-specific
Figure 4. Effect of secondary virus challenge on the
body weight of AID /  mice. (A) Mice of each genotype,
AID /  ( , n   7) or AID /  ( , n   8), were intrana-
sally inoculated with 1 PFU mPR8. (B) AID /  mice were
intranasally inoculated with 1 PFU mPR8 ( , n   8;  ,
n   6) or mock inoculated ( , n   7;  , n   6). Part of
the mice were depleted of CD8  CTL cell as described in
Materials and Methods by the administration of anti-CD8
mAb before challenge (  and  ). 42 d after inoculation,
mice were challenged intranasally with a lethal dose (1,000
PFU) of mPR8. The weights of the mice were monitored
daily for 4 wk after the challenge (A) or after the day of
the first antibody administration (B). Datum points rep-
resent the mean of infected mice. Error bars represent
standard deviation.
Table I. Virus Titers in the Lungs after Secondary Virus Challenge
Genotype of mice
Days after challenge AID   a AID   a
1 N.D.b —c
2 N.D. 5.44   0.96
5 N.D. 4.78   0.51
aThree to five mice were intranasally inoculated with 1 PFU mPR8
and 42 d later they were challenged intranasally with a lethal dose (100
LD50) of mPR8. At the indicated days after the challenge, lungs were
collected and homogenized. Virus titers in the homogenates were de-
termined on MDCK cells as described in Materials and Methods. Re-
sults are expressed as the mean titer    standard deviation of log10
TCID50/ml.
bNot detectable.
cNot done.T
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unmutated antibodies should play some role even in the
later phase of the primary infection.
A recent study has demonstrated the essential role of
IgM for protection from infection with influenza virus
because secreted sIgM-deficient (sIgM / ) mice that can
produce other isotypes show much higher susceptibility to
influenza virus (25). In the infection of sIgM /  mice
with influenza virus, survival rate is lower and lung virus
load is higher than those in wild-type mice. Because the
presence of protective IgM in unimmunized wild-type
mice was also reported (25, 26), the increased level of
IgM in AID /  mice may help their survival against influ-
enza virus infection.
Concluding Remark. In the primary influenza virus in-
fection, survival rates of AID /  and AID /  mice were
identical but the morbidity of AID /  mice was somewhat
severer than that of AID /  mice. In the secondary infec-
tion with the lethal dose, complete protection from death
was observed in both mice but only AID /  mice showed
severe morbidity. Depletion of CD8  CTL did not affect
the survival of AID /  mice in the secondary infection.
Taken together, unmutated IgM appears to be able to con-
trol virus replication to the extent that prevents animals
from death but unable to eliminate virus quickly and com-
pletely, thus resulting in severer morbidity. It is worth not-
ing that antigen-induced high titers of unmutated IgM pro-
tected AID /  mice from the lethal dose of secondary
influenza virus challenge. CSR and SHM appear to play a
vital role for the efficient protection in the primary as well
as secondary infection, although their involvement is not
absolute in survival of the animals.
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